Ono Pharmaceutical Co., Ltd.
4528.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 0.60 | 0.85 | 7.74 |
| FCF Yield | 9.88% | 7.58% | 3.58% | 1.09% |
| EV / EBITDA | 7.60 | 5.64 | 24.48 | 36.69 |
| Quality | ||||
| ROIC | 5.32% | 15.66% | 14.61% | 13.02% |
| Gross Margin | 69.61% | 74.71% | 75.39% | 74.12% |
| Cash Conversion Ratio | 1.39 | 0.86 | 1.11 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.87% | 11.63% | 13.08% | 7.31% |
| Free Cash Flow Growth | -17.10% | -38.10% | 192.85% | -7.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.63 | -0.86 | -0.54 | -0.49 |
| Interest Coverage | 11.23 | 712.24 | 155.49 | 131.48 |
| Efficiency | ||||
| Inventory Turnover | 1.98 | 2.61 | 2.46 | 2.24 |
| Cash Conversion Cycle | 65.54 | 64.17 | 20.48 | 70.07 |